Journal article

Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population

Anna R Giuliano, Elmar A Joura, Suzanne M Garland, Warner K Huh, Ole-Erik Iversen, Susanne K Kjaer, Alex Ferenczy, Robert J Kurman, Brigitte M Ronnett, Mark H Stoler, Oliver M Bautista, Erin Moeller, Michael Ritter, Christine Shields, Alain Luxembourg

GYNECOLOGIC ONCOLOGY | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2019

Abstract

OBJECTIVE: Nine-valent human papillomavirus (9vHPV) vaccine efficacy against disease and cervical surgeries related to all nine vaccine components was assessed compared with a historic placebo population. This was not assessed in the 9vHPV vaccine efficacy trial since the trial was quadrivalent HPV (qHPV) vaccine-controlled, efficacy was measured for the five HPV types covered only by 9vHPV vaccine (HPV31/33/45/52/58), but not the four types covered by both vaccines (HPV6/11/16/18). METHODS: Three international, randomized, double-blind studies were conducted using the same methodology. In the 9vHPV vaccine study (NCT00543543), 7106 and 7109 women received 9vHPV or qHPV vaccine, respectively..

View full abstract